,Canonical_Smiles,drug_name,drug_type,Label
0,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
1,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@@H]13,Eplerenone,P450_HFLA-Substrate,negative
2,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@@]21C,lithocholic_acid,3A4-Substrate,negative
3,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
4,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digitoxin,SUL-Substrate,negative
5,O=NN1CCC[C@H]1c1cccnc1,N_nitroso_nornicotine,3A4-Substrate,negative
6,COCCCOc1ccnc(CSc2nc3ccccc3[nH]2)c1C,rabeprazole_thioether,2E1-Substrate,negative
7,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
8,O=c1ccc2ccccc2o1,Coumarin,-,negative
9,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,Almotriptan,2D6-Substrate,negative
10,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,Cefotiam,Solute_carrier_family_22_member_8-Substrate,negative
11,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
12,CC(C)(C)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Terfenadine,P450_HFLA-Substrate,negative
13,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
14,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
15,CC(C)O,Isopropanol,2E1-Inducer,negative
16,CC(NCC(O)COc1cccc2ccccc12)C(C)(C)C,tert_butyl_propranolol,2D6-Substrate,negative
17,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
18,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
19,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Vasopressin,Solute_carrier_family_12_member_1-Inducer,negative
20,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Glyceryl Trinitrate,GST-Inducer,negative
21,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate,negative
22,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb12,3A4-Substrate,negative
23,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-,negative
24,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
25,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
26,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
27,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,P450_HFLA-Substrate,negative
28,Nc1nc(NC2CC2)c2ncn([C@@H]3C=C[C@H](CO)C3)c2n1,Abacavir,-,negative
29,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
30,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
31,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
32,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
33,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
34,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
35,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
36,COc1ccc2c(CN(C)C)cc(=O)oc2c1,DiMMAMC,2D6-Substrate,negative
37,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,Cytarabine,Multidrug_resistance_protein_1-Inducer,negative
38,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
39,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
40,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
41,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
42,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,Rifabutin,-,negative
43,Cc1nccn1C[C@H]1CCc2c(c3ccccc3n2C)C1=O,Ondansetron,2E1-Substrate,negative
44,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
45,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
46,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
47,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc2c1OCO2,Oxodipine,-,negative
48,CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@@H]2OC(=CCCCC(=O)O)C[C@@H]21,Epoprostenol,2C9-Substrate,negative
49,NC[C@H](O)c1ccc(O)cc1,Octopamine,N_acetyltransferase-Substrate,positive
50,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,Fosphenytoin,-,negative
51,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
52,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,Flurbiprofen,-,negative
53,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
54,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,2E1-Inhibitor,negative
55,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
56,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
57,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,Diosmectite,1B1-Inhibitor,negative
58,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
59,CCCc1cc(=O)[nH]c(=S)[nH]1,Propylthiouracil,GST-Inhibitor,negative
60,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate,negative
61,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
62,CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,Clotiapine,P450_HFLA-Substrate,negative
63,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
64,O=C1C=C2CN(Cc3ccccc3Cl)CCC2S1,2_oxo_ticlopidine,2D6-Substrate,negative
65,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
66,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Tamoxifen,19A-Inhibitor,negative
67,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
68,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
69,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,Tecastemizole,-,negative
70,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,Morphine,2D6-Substrate,negative
71,CC(=O)Nc1ccccc1,Acetanilide,-,negative
72,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
73,CN(C)CC(Oc1ccccc1)Oc1ccccc1,Medifoxamine,-,negative
74,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,muraglitazar,2E1-Substrate,negative
75,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
76,CC(=O)[C@H]1CC[C@H]2[C@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@@H]3[C@H](O)C[C@]12C,Medrysone,2E1-Inhibitor,negative
77,NCCc1ccc(O)c(O)c1,Dopamine,19A-Inhibitor,negative
78,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
79,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
80,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
81,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,progesterone,2D6-Substrate,negative
82,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
83,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,Astemizole,P450_HFLA-Substrate,negative
84,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Substrate,negative
85,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
86,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
87,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,Fenofibrate,-,negative
88,Cc1c(F)c(N2CCN[C@@H](C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,Grepafloxacin,-,negative
89,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
90,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
91,c1ccccc1,Benzene,-,negative
92,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
93,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@H]3SC(=O)NC3=O)cc1)O2,troglitazone,2C8-Substrate,negative
94,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
95,CC1(C)O[C@H]2CO[C@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@H]2O1,Topiramate,-,negative
96,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
97,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
98,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
99,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
100,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Teniposide,-,negative
101,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,Cinacalcet,2D6-Substrate,negative
102,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
103,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,Mifepristone,P450_HFLA-Inhibitor,negative
104,N=O,Nitric Oxide,GST-Inducer,negative
105,Oc1ccccc1,Phenol,2E1-Substrate,negative
106,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,Teriparatide,24A-Inhibitor,negative
107,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,genistein,1A2-Substrate,negative
108,COc1ccc(C(c2ccc(OC)cc2)C(Cl)(Cl)Cl)cc1,methoxychlor,2C19-Substrate,negative
109,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
110,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
111,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
112,Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,2D6-Substrate,negative
113,CNCc1cc(=O)oc2cc(OC)ccc12,MMAMC,2D6-Substrate,negative
114,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
115,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
116,Cc1ccc(C(C)C)cc2c(C)ccc1-2,Guajazulen,1A2-Substrate,negative
117,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2D6-Inhibitor,negative
118,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
119,CC(N)Cc1ccc(O)cc1,Hydroxyamfetamine,2D6-Substrate,negative
120,Cn1c(=O)[nH]c2ncn(C)c2c1=O,Paraxanthine,-,negative
121,CCCO,Propanol,-,negative
122,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
123,C#CC1(O)C=CC2C3CCC4=CC(=O)CCC4C3CCC21CC,Gestodene,-,negative
124,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,Cyclobarbital,HLp2-Inducer,negative
125,O=C(O)C/C=C/C[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,bisnor,3A4-Substrate,negative
126,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
127,Cc1ncc([N+](=O)[O-])n1CCO,Metronidazole,-,negative
128,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
129,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Chlorphenamine,Methyltransferase-Inducer,negative
130,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
131,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O,Dihydrostreptomycin,3A4-Substrate,negative
132,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Gefitinib,2D6-Inhibitor,negative
133,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,Sulfadoxine,-,negative
134,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3)cc2o1,7_benzyloxy_4_trifluoromethyl_coumarin,2C19-Substrate,negative
135,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
136,[Ag],Silver,Probable_low_affinity_copper_uptake_protein_2-Inhibitor,negative
137,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
138,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
139,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
140,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2,2_acetylamino_fluorene,1A2-Substrate,negative
141,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
142,O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,Efavirenz,2D6-Inhibitor,negative
143,CN1CCC23CCCCC2C1Cc1ccc(O)cc13,Dextrorphan,2D6-Substrate,negative
144,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
145,CN(C)CCCN1c2ccccc2Sc2ccccc21,promazine,2E1-Substrate,negative
146,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
147,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
148,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
149,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO,Tezosentan,-,negative
150,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,Mibefradil,P450_HFLA-Inhibitor,negative
151,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
152,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Prochlorperazine,2D6-Substrate,negative
153,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
154,CC[C@@H]1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,Tofisopam,3A4-Inhibitor,negative
155,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
156,C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor,negative
157,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
158,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
159,C=CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_13,3A4-Substrate,negative
160,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,Clemastine,2D6-Inhibitor,negative
161,[Cl-].[K+],Potassium Chloride,Solute_carrier_family_12_member_2-Substrate,negative
162,FC(F)(F)C(Cl)Br,halothane,2E1-Substrate,negative
163,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
164,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
165,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,2E1-Substrate,negative
166,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
167,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
168,COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)C13,18_methoxy_coronaridine,2D6-Substrate,negative
169,CN1C(=O)NC(=O)[C@@](C)(C2=CCCCC2)C1=O,hexobarbital_R,2C19-Substrate,negative
170,CCN(CC)C(=O)c1cccc(C)c1,Diethyltoluamide,2E1-Substrate,negative
171,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
172,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,Tolbutamide,CP2CI-Substrate,negative
173,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
174,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,Clonazepam,N_acetyltransferase-Substrate,positive
175,Clc1ccc(CO[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Miconazole,19A-Inhibitor,negative
176,CC(NC(N)=O)c1cc2ccccc2s1,ABT_66193,2D6-Substrate,negative
177,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
178,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,Amobarbital,Coumarin_7_hydroxylase-Inducer,negative
179,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2D6-Inhibitor,negative
180,C=CCc1ccc(OC)c(OC)c1,methyl_eugenol,2D6-Substrate,negative
181,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Fluphenazine,2E1-Inhibitor,negative
182,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
183,NN=O,Nitrosamine,-,negative
184,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)[C@@H]1c1ccccc1[N+](=O)[O-],Nisoldipine,P450_HFLA-Substrate,negative
185,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
186,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,Budesonide,SUL-Substrate,negative
187,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Pergolide,2D6-Inhibitor,negative
188,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
189,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,-,negative
190,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,Yohimbine,2D6-Substrate,negative
191,OCCSCCCCCCCCCCSCCO,Tiadenol,UGT-Inducer,negative
192,CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1,diuron,2E1-Substrate,negative
193,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
194,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
195,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
196,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
197,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,SUL-Substrate,negative
198,Clc1cccc(N2CCNCC2)c1,m-Chlorophenylpiperazine,2D6-Substrate,negative
199,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,CP2CI-Substrate,negative
200,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,-,negative
201,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
202,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
203,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
204,C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C,org_30659_tosagestin,2C19-Substrate,negative
205,c1ccc2cc(COC3CCNCC3)ccc2c1,Litoxetine,-,negative
206,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
207,O=C(O)Cc1cc(O)ccc1Nc1c(Cl)cccc1Cl,5_hydroxy_diclofenac,2C9-Substrate,negative
208,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
209,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
210,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Apomorphine,SUL-Substrate,negative
211,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
212,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
213,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Codeine,P450_HFLA-Substrate,negative
214,CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1,methadone_R,2D6-Substrate,negative
215,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
216,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2D6-Inhibitor,negative
217,CO[C@H]1C=CO[C@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifamycin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
218,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
219,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,buprenorphine,2C8-Substrate,negative
220,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,13_cis_retinoic_acid,2E1-Substrate,negative
221,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,Folic Acid,N_acetyltransferase-Substrate,positive
222,CC1=CC(=O)c2ccccc2C1=O,Menadione,2E1-Substrate,negative
223,COCCCOc1ccnc(CC(=O)c2nc3ccccc3[nH]2)c1C,Rabeprazole,-,negative
224,CNC(=O)Oc1cccc2ccccc12,carbaryl,2E1-Substrate,negative
225,CS(=O)(=O)OC[C@H](O)[C@H](O)COS(C)(=O)=O,Treosulfan,1A2-Inhibitor,negative
226,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,ezlopitant,2D6-Substrate,negative
227,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
228,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
